Public Release: 

Low stent thrombosis rates with primary PCI, regardless of antithrombotic choice

Later stent thrombosis carried highest risks of increased mortality

PCR

(PARIS, FRANCE) - Stent thrombosis following urgent angioplasty for acute heart attack occurred in less than 1% of patients in a large, "real-world" registry, regardless of whether the antithrombotic treatment used during the procedure was bivalirudin, heparin alone, or a GP IIb/IIIa inhibitor (typically in combination with heparin).*

However, patients who experienced a stent thrombosis between days 2 and 30, regardless of drug regimen, were more likely to die within one year than were patients who developed stent thrombosis within the first 24 hours of their procedure.

"What is new, to my knowledge, is the relationship between stent thrombosis timing and mortality at one year," said Dr. Per Grimfjard of Vasteras Hospital / Uppsala University, Sweden, who presented the nationwide Swedish Registry data here at EuroPCR 2015. "In my opinion, a possible explanation is that a stent thrombosis that happens once the patient has left the hospital is likely to cause a more substantial infarction, the reason being longer delay from symptoms to revascularisation."

A more substantial myocardial infarction typically leads to more heart failure and arrhythmia long term, he added.

A number of recent studies have raised concerns that bivalirudin, a newer, more expensive drug used to prevent clot formation during emergency angioplasty, may increase the risk of clots inside the newly implanted stents compared with the older drug, heparin. Rates of stent thrombosis, however, have differed substantially between studies.

Grimfjard and colleagues decided to review stent thrombosis rates by drug choice among more than 30,000 patients treated with primary PCI for ST-elevation myocardial infarction (STEMI) between January 2007 and July 2014 in the Swedish Coronary Angiography and Angioplasty Register (SCAAR). They found that rates of stent thrombosis were low across all three drug groups analyzed (bivalirudin = 0.84%, heparin = 0.94%, and GP IIb/IIIa inhibitor = 0.83%).

For all three drugs, however, mortality at one year was numerically higher if the stent thrombosis occurred between 2 and 30 days, as compared with day 0-1 post-PPCI.

The findings regarding the timing of stent thrombosis do not offer interventionalists any insights into choice of antithrombotic treatment, Grimfjard cautioned. The Swedish investigators are currently enrolling patients in a 6000-patient, registry-based, randomised clinical trial called SWEDEHART-Validate looking at heparin-only vs. bivalirudin-plus-optional low-dose heparin in STEMI and non-STEMI patients undergoing PCI.

"Hopefully this large randomised trial will bring clarity to the choice of antithrombotic treatment strategy in these patients," Grimfjard said.

* 77% of patients in the bivalirudin group also received heparin, and 3.6% received a GPI prior to or during the PCI procedure. In the GPI group, 77% of patients also received heparin.

###

This study is part of the SWEDEHEART-VALIDATE trial sponsored by Uppsala Clinical Research Center (UCR), Uppsala University and financially supported by The Swedish Heart and Lung foundation, Astra Zeneca, and the Medicines Company. Grimfjard has no disclosures.

Contact: Dr. Per Grimfjärd <per.grimfjard@ltv.se>

Associated EuroPCR 2015 Session: Hot Line: Antithrombotic Strategies, 14:40-16:40 CEST, Thursday May 21, Room Maillot

Notes to Editors

For more information on the abstracts featured in this press release, please contact Isabelle Uzielli, email: iuzielli@europcr.com

Further information on press registration may be found at http://www.europcr.com/page/press/619-press.html

What is EuroPCR?

EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore; London, UK; Dubai, EAU; Johannesburg, RSA; Istanbul, Turkey; Chengdu, China; and Tokyo, Japan.

For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR, PCR Istanbul Peripheral, PCR-CIT China Chengdu Valves, PCR Tokyo Valves & PCR, please contact: Anne-Sophie Lartigau at aslartigau@europa-organisation.com.

For more information, please visit http://www.europcr.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.